Cytokinetics, Incorporated (CYTK) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Cytokinetics, Incorporated (CYTK) Bundle
Designed for accuracy, our Cytokinetics DCF Calculator helps you evaluate Cytokinetics, Incorporated (CYTK) valuation using real-world financial data while offering complete flexibility to modify all key parameters for improved projections.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 26.9 | 55.8 | 70.4 | 94.6 | 7.5 | 8.8 | 10.3 | 12.1 | 14.2 | 16.6 |
Revenue Growth, % | 0 | 107.79 | 26.15 | 34.3 | -92.04 | 17.1 | 17.1 | 17.1 | 17.1 | 17.1 |
EBITDA | -93.0 | -86.8 | -176.3 | -329.4 | -456.7 | -8.8 | -10.3 | -12.1 | -14.2 | -16.6 |
EBITDA, % | -346.28 | -155.45 | -250.39 | -348.25 | -6064.86 | -100 | -100 | -100 | -100 | -100 |
Depreciation | 1.3 | 1.8 | 9.6 | 8.4 | 11.9 | 2.3 | 2.7 | 3.2 | 3.7 | 4.3 |
Depreciation, % | 4.81 | 3.28 | 13.68 | 8.88 | 157.93 | 26.13 | 26.13 | 26.13 | 26.13 | 26.13 |
EBIT | -94.3 | -88.6 | -186.0 | -337.8 | -468.6 | -8.8 | -10.3 | -12.1 | -14.2 | -16.6 |
EBIT, % | -351.09 | -158.73 | -264.07 | -357.13 | -6222.79 | -100 | -100 | -100 | -100 | -100 |
Total Cash | 225.1 | 464.1 | 471.6 | 782.6 | 614.8 | 8.8 | 10.3 | 12.1 | 14.2 | 16.6 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | 5.2 | 4.4 | 51.8 | .1 | 1.3 | 2.1 | 2.4 | 2.9 | 3.3 | 3.9 |
Account Receivables, % | 19.22 | 7.92 | 73.58 | 0.15541 | 17.04 | 23.58 | 23.58 | 23.58 | 23.58 | 23.58 |
Inventories | .0 | -4.4 | -51.8 | -.1 | .0 | -1.4 | -1.7 | -2.0 | -2.3 | -2.7 |
Inventories, % | 0 | -7.92 | -73.58 | -0.15541 | 0 | -16.33 | -16.33 | -16.33 | -16.33 | -16.33 |
Accounts Payable | 8.2 | 8.1 | 21.1 | 25.6 | 21.5 | 3.6 | 4.2 | 4.9 | 5.7 | 6.7 |
Accounts Payable, % | 30.37 | 14.42 | 29.94 | 27.08 | 285.62 | 40.36 | 40.36 | 40.36 | 40.36 | 40.36 |
Capital Expenditure | -2.6 | -11.1 | -48.9 | -11.3 | -1.4 | -2.3 | -2.7 | -3.1 | -3.7 | -4.3 |
Capital Expenditure, % | -9.75 | -19.8 | -69.39 | -11.98 | -18.8 | -25.95 | -25.95 | -25.95 | -25.95 | -25.95 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -115.5 | -114.3 | -209.4 | -349.6 | -468.6 | -8.8 | -10.3 | -12.1 | -14.2 | -16.6 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -113.9 | -118.4 | -235.6 | -348.0 | -463.5 | -26.1 | -9.8 | -11.5 | -13.4 | -15.8 |
WACC, % | 8.07 | 8.07 | 8.07 | 8.07 | 8.07 | 8.07 | 8.07 | 8.07 | 8.07 | 8.07 |
PV UFCF | ||||||||||
SUM PV UFCF | -62.2 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | -16 | |||||||||
Terminal Value | -265 | |||||||||
Present Terminal Value | -179 | |||||||||
Enterprise Value | -242 | |||||||||
Net Debt | 643 | |||||||||
Equity Value | -884 | |||||||||
Diluted Shares Outstanding, MM | 97 | |||||||||
Equity Value Per Share | -9.16 |
What You Will Get
- Real CYTK Financial Data: Pre-filled with Cytokinetics' historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Cytokinetics' intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Customizable Clinical Trial Parameters: Adjust essential inputs such as patient enrollment rates, treatment efficacy, and study duration.
- Real-Time Data Analysis: Provides instant insights into trial results, statistical significance, and other key metrics.
- High-Precision Forecasting: Utilizes Cytokinetics' real-world data for accurate projections and outcomes.
- Effortless Scenario Simulation: Easily evaluate various clinical scenarios and their potential impacts on results.
- Efficiency Booster: Streamline the process by avoiding the complexities of building trial models from the ground up.
How It Works
- Step 1: Download the Excel file for Cytokinetics, Incorporated (CYTK).
- Step 2: Review the pre-filled financial data and forecasts specific to Cytokinetics.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model refresh in real-time as you modify your assumptions.
- Step 5: Evaluate the results and apply them to your investment strategies.
Why Choose This Calculator for Cytokinetics, Incorporated (CYTK)?
- Designed for Experts: A sophisticated tool utilized by researchers, financial analysts, and investment advisors.
- Accurate Data: Cytokinetics’ historical and projected financials are preloaded for precision.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth experience.
Who Should Use Cytokinetics, Incorporated (CYTK) Products?
- Healthcare Investors: Make informed investment choices with cutting-edge pharmaceutical insights.
- Clinical Researchers: Streamline your research with access to comprehensive data on drug efficacy.
- Pharmaceutical Consultants: Quickly tailor presentations or reports for clients in the biotech sector.
- Biotech Enthusiasts: Enhance your knowledge of drug development processes through real-life case studies.
- Educators and Students: Utilize it as a hands-on resource in life sciences and pharmaceutical courses.
What the Template Contains
- Pre-Filled DCF Model: Cytokinetics’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Cytokinetics’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.